Okomera specializes in automated 3D organoid screening technology that accelerates access to improved, precision-based cancer therapies. Their goal is to advance personalized medicine by providing healthcare actors with powerful tools to analyze how tumors respond to various therapies.
Okomera integrates standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity.
About the solution
They have developed a miniaturized 3D assay to help clinical decision. Using a biopsy of the tumor, Okomera’s cell culture technology includes: a fluidic machine, reagents, and a software analysis designed to estimate and identify the best drug treatment for each cancer patient.
The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology,
About the solution
The Institut Pasteur’s outstanding research is facilitated by the development of a technological environment of the highest standard, with core facilities for nanoimaging (cryo-electron microscopy, cryo-electron tomography, etc.), computational biology and artificial intelligence.
Voisin Consulting Life Sciences (VCLS) is a team of around 300 life sciences professionals, committed to delivering innovative therapies to patients. From discovery to patients, their team of HealthTech product specialists offers integrated solutions from development planning, manufacturing, quality and control, nonclinical and clinical testing, clinical trial operations, safety monitoring, registration and commercialization, post-launch.
About the solution
With a presence in North America, Europe and Southeast Asia, they design global strategies and adapt execution in each market – accounting for local medical practices, regulatory frameworks and reimbursement landscapes. They have been interacting for more than two decades with regulators, payers and key opinion leaders in these markets. The privileged relationships that they have developed facilitate formal and informal dialogue between the industry and health authorities.
Roowin is a privately owned Contract Research Organisation (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value added fine chemistry, Roowin offers a large range of chemical services.
They support their customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches (about 20 kg).
About the solution
They are a french company specializing in high-value fine chemistry, is well-equipped to support biotech companies in need of GLP and GMP lots for toxicology studies and IND applications. With expertise in GMP synthesis and a focus on assisting customers from early research to later stages, Roowin is a potential partner for biotechs developing new clinical candidates.
BIOASTER is the first Institute for Technological Innovation in Microbiology in France (Lyon and Paris, Pasteur Institute). They are Non-for-profit Technology Research Institute, active in the field of vaccine, immunomodulation, microbiota, anti-infectives, and IVD. With BIOASTER, each project benefits from the right scientific and technology mix to address specific issues, quality in execution to meet high-standard requirements and case-by-case financial risk-sharing partnerships. Their industrial partners come from a wide range of industries, including pharma, biotech, animal health, nutrition and diagnostics.
About the solution
Examples of partnership themes include for vaccine : Memory response /Longitudinal study, Efficacy, Memory response /Longitudinal study,correlate of protection, Breadth of protection, benchmarking with competitives vaccines, vaccine & adjuvant MOA, Exploratory research, preclinical & clinical biomarkers identification, system serology, immunometabolism (immunophenotyping at single cell), microbiota & immunity, host pathogen interaction.
Examples of partnership themes include for bioprocess- bioproduction & CMC: biomarkers identification for batch success/batch failure, digital tween & machine learning/deep Learning, method development & benchmarking, antigen characterization, potency assays development, Host Cell Proteins identification, CMC methods for in vitro mRNA production, mRNA formulation.
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 40 years, covering the drug development process from early screening through regulatory submission.
About the solution
Porsolt provides discovery and preclinical services (safety & efficacy) including in vitro assays, pathophysiological models in multiple species and cell lines, customized procedures, and tailored solutions. They offer to support drug development using high throughput screening, high content analysis, and high content histology platforms, drug formulation analysis, and bioanalytical services.
Their vast expertise covers the following areas: psychiatric and neurological disorders, cardiac and vascular diseases, oncology, pain, inflammation, gastrointestinal disorders, liver diseases, metabolic and eating disorders, respiratory diseases, dermatology, medical devices, and predictive toxicity of compounds.
Aurora was founded in 2019 by Jan Laarman and Thomas Parias, after 5 years of in-house industrial research, two entrepreneurs passionate about innovation in the field of healthcare. Their goal is to become a major player in the field of sterilization using natural plasma as the sole sterilizing agent.
About the solution
The company develops a unique patent-protected sterilization method based on an oxygen plasma. It enables the sterilization of complex and sensitive devices that can’t be sterilized with existing technologies. It operates at low temperature (30-40°C). It is an environmental-friendly sterilization technology of medical devices.
ERBC group is a leader in discovery and non-clinical studies, offering to healthcare and chemical professionals a comprehensive range of discovery and preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity.
About the solution
At ERBC Group, THEY STRATEGIZE your approach to make your drug development a SUCCESS: – Build on most relevant translational models – Select best predictive biomarkers – Choose state-of-the-art technologies.
SEQENS is a global partner in health, personal care and specialty ingredients. They empower innovation to bring the best solutions to our customers, with a constant concern for sustainability. Relying on the skills of 3300 employees, they leverage a worldwide manufacturing network, and state-of-the-art R&D centers. As an end-to-end player across the value chain, SEQENS offers a broad range of active ingredients, pharmaceutical intermediates, personal care & specialty ingredients. They innovate, develop and industrialize the most demanding molecules, and implement the best available technologies.
As a leading player of the health industry, SEQENS is committed to the therapies of the future and personalized medicine.
Driven by a culture of excellence and a strong entrepreneurial spirit, they share values such as unity, agility, and reactivity. They provide the highest level of service and quality to more than 1500 customers around the world while acting ethically in accordance to our strong CSR program.
About the solution
Streamline your development process with Seqens’ one-stop-shop CDMO services. They offer integrated support for all stages of your program, from discovery and preclinical studies to clinical development, market authorization, and even ongoing commercial manufacturing. This ensures seamless handoffs and reduces overall development timelines.
Oxeltis is a medicinal chemistry services company created in 2010 in Montpellier, France, by former researchers from Idenix Pharmaceuticals (formerly MSD). The company has a small-scale custom synthesis business and hit and lead optimization services in various areas, such as antivirals, antibiotics, and anticancer compounds. Oxeltis’ scientific team comprises 21 experienced chemists with recognized expertise in specific areas of organic synthesis: heterocycles, macrocycles, nucleosides/nucleotides, phosphoramidites, iminosugars, modified sugars, oligosaccharides, and PROTACs. Oxeltis services includes also route scouting and up to 50-100g synthesis. Oxeltis works with European, Japanese, and North American start-ups, pharma companies, and research institutions.
About the solution
Oxeltis team is focused on speed of delivery, quality, and confidentiality of the services and collaborations it develops. Oxeltis has completed more than 35 projects with complex and multi-step synthetic chemistry for pharmaceutical and biotechnology companies, including five of the ten largest global pharmaceutical companies. Several drug candidates delivered to its customers are in clinical development.
